The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Drug–drug interactions that interfere with statin metabolism
Abstract
INTRODUCTION: Lipid-lowering drugs, especially hydroxymethylglutaryl-CoA reductase inhibitors (statins), are widely used in the treatment and prevention of atherosclerotic diseases. The benefits of statins are well documented. However, myotoxic side effects, which can sometimes be severe, including myopathy or rhabdomyolysis, have been associated with the use of statins. In some cases, this toxicity is associated with pharmacokinetic alterations. Potent inhibitors of CYP 3A4 significantly increase plasma concentrations of the active forms of simvastatin, lovastatin and atorvastatin. Fluvastatin is metabolized by CYP2C9, while pravastatin, rosuvastatin and pitavastatin are not susceptible to inhibition by any CYP. AREAS COVERED: This review discusses the pharmacokinetic aspects of the drug-drug interaction with statins and genetic polymorphisms in CYPs, which are involved in the metabolism of statins, and highlights the importance of establishing a system utilizing electronic medical information practically to avoid adverse drug reactions. EXPERT OPINION: An understanding of the mechanisms underlying statin interactions will help to minimize drug interactions and develop statins that are less prone to adverse interactions. Quantitatively analyzed information for the low-density lipoprotein cholesterol lowering effects of statin based on electronic medical records may be useful for avoiding the adverse effect of statins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Coadministration of other drugs that are metabolized through the CYP450 pathway such as certain antifungals, human immunodeficiency virus protease inhibitors, fibrates, and macrolide antibiotics increases the risk of both DILI and rhabdomyolysis due to altered statin metabolism.17,18”
From Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge (2025) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
Statin Safety: A Systematic Review
Law, M., & Rudnicka, A. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.010 · Cited by 808
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
Plasma concentrations of active simvastatin acid are increased by gemfibrozil
Backman, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108507 · Cited by 264
Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
Neuvonen, P. J., & Jalava, K.-M. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90167-8 · Cited by 238
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
Kivistö, K. T., Kantola, T., & Neuvonen, P. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00034.x · Cited by 171
Statin safety: an assessment using an administrative claims database
Cziraky, M. J., Willey, V. J., McKenney, J. M., Kamat, S. A., Fisher, M. D., Guyton, J. R., Jacobson, T. A., & Davidson, M. H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.011 · Cited by 130
Clinical pharmacokinetics of statins
Garcia, M. J., Reinoso, R. F., Sanchez Navarro, A., & Prous, J. R. (2003) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2003.25.6.769652 · Cited by 121
Research works printed but not linked: 128
- Rodwell VW, 1976, Adv Lipid Res, 14, 1, 10.1016/B978-0-12-024914-5.50008-5 · DOI · Paper page
- 10.1038/343425a0 · DOI · Paper page
- 10.1016/0014-5793(76)80996-9 · DOI · Paper page
- 10.1186/CVM-2-5-205 · DOI · Paper page
- 10.1002/pds.977 · DOI
- 10.2165/00002018-200225090-00004 · DOI · Paper page
- 10.1002/pds.1895 · DOI
- 10.1016/0002-9149(88)90004-5 · DOI · Paper page
- 10.1001/archinte.1996.00440170097011 · DOI · Paper page
- 10.2165/00002018-200730020-00005 · DOI
- 10.1002/tera.1420500104 · DOI
- 10.1006/taap.1997.8174 · DOI
- 10.1016/S0022-2828(95)92163-X · DOI
- Smith PF, 1991, J Pharmacol Exp Ther, 257, 1225, 10.1016/S0022-3565(25)24759-0 · DOI
- 10.1016/S0002-9149(96)00742-4 · DOI · Paper page
- 10.1248/bpb.20.104 · doi:10.1248/bpb.20.104
- Molden E, 2007, Tidsskr Nor Laegeforen, 127, 1660
- 10.1161/CIRCULATIONAHA.106.624890 · DOI · Paper page
- Nakai D, 2001, J Pharmacol Exp Ther, 297, 861, 10.1016/S0022-3565(24)29609-9 · DOI · Paper page
- 10.1016/j.amjcard.2005.12.007 · DOI · Paper page
- 10.2165/00002512-200724050-00006 · DOI
- 10.1517/14740338.5.1.145 · DOI
- 10.1007/BF03167690 · DOI
- 10.1345/aph.1A333 · doi:10.1345/aph.1a333 · Paper page
- 10.1146/annurev.pa.32.040192.001153 · DOI · Paper page
- 10.1038/clpt.2008.165 · DOI
- 10.2165/00003088-200241050-00003 · DOI · Paper page
- 10.1016/j.pharmthera.2006.03.003 · DOI · Paper page
- 10.2165/00003088-200847070-00003 · DOI · Paper page
- 10.2165/00003088-200342130-00005 · DOI · Paper page
- 10.1007/s002280100329 · DOI · Paper page
- 10.1093/qjmed/hcn089 · DOI
- 10.1016/j.clpt.2006.09.003 · DOI · Paper page
- 10.2165/00003088-200039060-00002 · DOI · Paper page
- 10.1177/009127002401102876 · DOI
- 10.1515/DMDI.2004.20.1-2.25 · DOI
- 10.1016/j.atherosclerosis.2010.10.006 · DOI
- 10.1080/03602530701836662 · DOI
- 10.1007/s00216-008-2291-6 · DOI · Paper page
- 10.1080/00498250802334391 · DOI
- 10.1097/00041433-200212000-00007 · DOI
- 10.1016/j.amjcard.2003.08.078 · DOI
- 10.1093/jnci/90.16.1225 · DOI · Paper page
- 10.1016/S0009-9236(99)70037-8 · DOI · Paper page
- 10.1006/bbrc.1999.0752 · DOI · Paper page
- 10.1067/mcp.2000.104391 · doi:10.1067/mcp.2000.104391
- 10.1067/mcp.2000.108506 · DOI · Paper page
- 10.1097/00008571-200107000-00008 · DOI
- Moes DJ, 2014, CPT, 3, e100
- 10.2174/138920008783331130 · doi:10.2174/138920008783331130
- 10.1038/86882 · DOI · Paper page
- 10.1097/01.fpc.0000114762.78957.a5 · DOI · Paper page
- 10.1016/j.clpt.2005.08.003 · DOI · Paper page
- 10.1080/00498250500256367 · doi:10.1080/00498250500256367
- 10.1016/S0009-9236(03)00121-8 · DOI
- 10.12659/MSM.883272 · doi:10.12659/msm.883272
- 10.1023/A:1011077109233 · DOI
- 10.1592/phco.27.4.603 · DOI
- 10.1016/j.amjcard.2004.07.080 · DOI · Paper page
- 10.1592/phco.20.13.1066.35033 · DOI
- 10.1016/S0140-6736(05)78613-X · DOI
- 10.1016/S0006-2952(95)02175-2 · DOI
- Regazzi MB, 1993, Transplant Proc, 25, 2732
- 10.1016/j.clpt.2003.09.011 · DOI
- 10.2165/00003495-200363040-00003 · DOI
- 10.1016/j.clpt.2004.03.010 · DOI · Paper page
- 10.1124/dmd.106.009290 · DOI · Paper page
- 10.1067/mcp.2002.128469 · DOI · Paper page
- 10.1007/s002280050408 · DOI
- 10.1046/j.1365-2362.33.s2.6.x · DOI · Paper page
- 10.1007/s002280000127 · DOI
- 10.1046/j.1365-2796.1999.00610.x · DOI
- 10.1177/009127002401102731 · DOI
- 10.1097/MOL.0b013e3280555083 · DOI
- 10.1124/dmd.30.11.1280 · DOI · Paper page
- 10.1007/s002280050566 · DOI
- 10.1124/jpet.104.068536 · DOI · Paper page
- 10.1007/s10038-004-0188-6 · DOI
- 10.1124/dmd.107.015230 · DOI
- Prueksaritanont T, 1997, Drug Metab Dispos, 25, 1191
- 10.1067/mcp.2001.115542 · DOI · Paper page
- 10.1124/jpet.102.041921 · DOI · Paper page
- 10.1007/s11095-011-0564-9 · DOI
- 10.1517/17425255.4.1.1 · DOI · Paper page
- 10.1124/dmd.113.054767 · doi:10.1124/dmd.113.054767
- Dobrinska MR, 1988, Pharm Res, 5, S182
- Pan HY, 1993, Int J Clin Pharmacol, 31, 291
- 10.1002/j.1552-4604.1995.tb04015.x · DOI
- 10.1007/BF03190074 · DOI
- 10.1016/0002-9343(94)90230-5 · doi:10.1016/0002-9343(94)90230-5
- 10.1046/j.1365-2125.1998.00764.x · DOI · Paper page
- 10.1016/0140-6736(91)90872-M · DOI · Paper page
- 10.1016/S0009-9236(98)90130-8 · DOI · Paper page
- 10.1016/S0009-9236(98)90034-0 · DOI · Paper page
- 10.1053/cp.1999.v66.100453001 · doi:10.1053/cp.1999.v66.100453001 · Paper page
- 10.1111/j.1365-2125.2005.02462.x · DOI
- 10.1111/j.1365-2125.2011.03996.x · DOI
- 10.2133/dmpk.DMPK-12-RG-067 · DOI
- Jacobsen W, 1999, Drug Metab Dispos, 27, 173, 10.1016/S0090-9556(24)15273-7 · DOI
- 10.1067/mcp.2000.110216 · DOI · Paper page
- Thummel KE, 2001, Mol Pharmacol, 60, 1399, 10.1124/mol.60.6.1399 · DOI · Paper page
- 10.1016/S0006-291X(02)02742-0 · DOI
- 10.1074/jbc.M201323200 · DOI · Paper page
- 10.1007/s00228-003-0700-5 · DOI
- 10.1067/mcp.2000.111414 · DOI · Paper page
- 10.1046/j.1365-2125.2003.01972.x · DOI
- 10.1111/j.1472-8206.2006.00404.x · DOI
- 10.1111/bcp.12405 · DOI
- 10.1517/14656566.8.14.2315 · DOI
- 10.1111/j.1742-1241.2005.00461.x · DOI
- 10.1038/clpt.2012.163 · DOI · Paper page
- 10.1097/01.qai.0000167156.44980.33 · DOI · Paper page
- 10.1177/00912700222011148 · DOI
- 10.1016/j.clpt.2005.04.007 · DOI
- 10.1016/S0009-9236(98)90023-6 · DOI · Paper page
- 10.1067/mcp.2000.110537 · DOI
- 10.1111/j.1528-1167.2011.03118.x · doi:10.1111/j.1528-1167.2011.03118.x
- 10.1007/s00228-012-1369-4 · DOI
- 10.1016/S0009-9236(98)90067-4 · DOI · Paper page
- 10.1007/s00228-012-1403-6 · DOI
- 10.1007/s002280100298 · doi:10.1007/s002280100298
- 10.1016/S0009-9236(98)90151-5 · DOI · Paper page
- 10.1016/S0009-9236(98)90165-5 · DOI · Paper page
- Gehin M, 2014, Eur J Clin Pharmacol
- 10.1016/0002-9149(94)90626-2 · DOI · Paper page
- 10.1177/0091270006299138 · DOI
- 10.1016/S0002-9149(05)80024-4 · DOI
- 10.1093/ajh/6.11.375S · DOI
Cited by
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Muntean, D. M., Thompson, P. D., Catapano, A. L., Stasiolek, M., Fabis, J., Muntner, P., Serban, M.-C., & Banach, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.001 · Cited by 82
Metadata
- Authors
- Hirota, T., & Ieiri, I.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2015-06-10
- Volume
- 11
- Issue
- 9
- Pages
- 1435-1447
- ISSN
- 1742-5255
- 1744-7607
- Cited by
- 74
- References
- 9
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug–drug interactions that interfere with statin metabolism. https://app.cochat.ai/papers/10.1517/17425255.2015.1056149
- The paper
- Hirota, T., & Ieiri, I. (2015). Drug–drug interactions that interfere with statin metabolism. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2015.1056149
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.